Australia Markets closed

Bionomics Limited (BNO.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0240+0.0010 (+4.35%)
At close: 03:57PM AEDT
Full screen
Previous close0.0230
Bid0.0230 x 0
Ask0.0250 x 0
Day's range0.0220 - 0.0240
52-week range0.0220 - 0.0740
Avg. volume1,333,425
Market cap32.48M
Beta (5Y monthly)2.18
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

    Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of the full data set and in relevant subpopulations Favourable safety, tolerability and PK findings are consistent with a fast-acting non-sedating anxiolytic profileThe company is planning an End of Phase 2 (EoPh2) meeting to discuss BNC210’s late-stage SAD program 2H 2023 Webcast and conference call sch

  • GlobeNewswire

    Bionomics’ Half-Year Report

    ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value. The Company recently completed its Phase 2

  • GlobeNewswire

    Quarterly Activities and Cashflow Report

    ADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 December 2022 (Quarter) and up to the da